Key opinion leaders in breast cancer provide insight into data presented at the virtual San Antonio Breast Cancer Symposium 2020 with a focus on metastatic triple-negative breast cancer.

Data from the following abstracts are discussed:

“GS3-06. Biomarker Evaluation in the Phase 3 ASCENT Study of Sacituzumab Govitecan Versus Chemotherapy in Patients With Metastatic Triple-Negative Breast Cancer” (Hurvitz et al, SABCS 2020)

 Alterations in Tumor Tissue From 1440 Patients With Advanced Hormone Receptor-Positive HER2-Negative Breast Cancer (HR+/HER2

BC) or Triple-Negative Breast Cancer (TNBC) Screened for the IPATunity130 Randomized Phase 3 Trial” (Savage et al, SABCS 2020)

Videos

Metastatic Triple-Negative Breast Cancer

Breast cancer experts review data from the virtual San Antonio Breast Cancer Symposium 2020 in hormone epidermal growth factor receptor 2-positive breast cancer, then discuss the DESTINY-Breast01, HER2CLIMB, and NALA trials.

“Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer” (Modi et al, 2020)

“GS1-03. [Fam-] Trastuzumab Deruxtecan (T-DXd; DS-8201a) in Subjects With HER2-Positive Metastatic Breast Cancer Previously Treated With T-DM1: A Phase 2, Multicenter, Open-Label Study (DESTINY-Breast01)” (Krop et al, SABCS 2019)

“PD3-06. Updated Results From DESTINY-Breast01, A Phase 2 Trial of Trastuzumab Deruxtecan (T-DXd) in HER2-Positive Metastatic BreastCancer” (Modietal, SABCS 2020)

“CNS Metastases in HER2-Positive Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan: DESTINY-Breast01 Subgroup Analyses (Jerusalem et al, ESMO Breast 2020

“Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer” (Murthy et al, 2020

“Tucatinib Versus Placebo Added to Trastuzumab and Capecitabine in Previously Treated HER2-Positive Metastatic Breast Cancer With and Without Brain Metastases (HER2CLIMB)” (Curigliano et al, ESMO Breast 2020, 137O

“Tucatinib Versus Placebo Added to Trastuzumab and Capecitabine for Patients With Previously Treated HER2-Positive Metastatic Breast Cancer With Brain Metastases (HER2CLIMB)” (Lin et al, ASCO 2020)

“PD13-04. Impact of Tucatinib on Health-Related Quality of Life in Patients With HER2-Positive Metastatic Breast Cancer With Stable and Active Brain Metastases” (Wardley et al, SABCS 2020 PD-1304)

“Neratinib + Capecitabine Versus Lapatinib + Capecitabine in Patients With HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Findings From the Multinational, Randomized, Phase III NALA Trial” (Saura et al, ASCO 2019)

“PS9-02. Neratinib + Capecitabine Sustains Health-Related Quality of Life (HRQoL) While Improving Progression-Free Survival (PFS) in Patients With HER2-Positive Metastatic Breast Cancer and ≥2 Prior HER2-Directed Regimens” (Moy et al, SABCS 2020 PS9-02)

“Trastuzumab Deruxtecan (DS-8201a) Versus Investigator’s Choice for HER2-Low Breast Cancer That Has Spread or Cannot Be Surgically Removed [DESTINY-Breast04]” (NCT03734029)

Metastatic Hormone Epidermal Growth Factor Receptor 2-Positive Breast Cancer

The expert panelists highlight data from the virtual San Antonio Breast Cancer Symposium 2020, focusing on hormone receptor-positive breast cancer.

“GS1-01. Primary Outcome Analysis of Invasive Disease-Free Survival for monarchE: Abemaciclib Combined with Adjuvant Endocrine Therapy for High Risk Early Breast Cancer” (O’Shaughnessy et al, SABCS 2020)

“GS1-02. Phase III Study of Palbociclib Combined With Endocrine Therapy (ET) in Patients With Hormone-Receptor-Positive (HR+), HER2-Negative Primary Breast Cancer and With High Relapse Risk After Neoadjuvant Chemotherapy (NACT): First Results From PENELOPE-B” (

“GS4-01. Results from CONTESSA: A Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2-, Hormone Receptor + (HR+) Metastatic Breast Cancer (MBC) Who Have Previously Received a Taxane” (

“GS3-00. First Results From a Phase III Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy (ET) +/- Chemotherapy (CT) in Patients (pts) with 1-3 Positive Nodes, Hormone Receptor-Positive (HR+) and HER2-negative (HER2-) Breast Cancer (BC) with Recurrence Score (RS) 

 25: SWOG S1007 (RxPonder)” (Kalinsky et al, SABCS 2020)

“GS2-02. 12-Year Results of Anastrozole Versus Tamoxifen For the Prevention of Breast Cancer in Postmenopausal Women With Locally Excised Ductal Carcinoma In-Situ” (

Pavani Chalasani, MD, University of Arizona Cancer Center

Articles

Metastatic Triple-Negative Breast Cancer

Metastatic Hormone Epidermal Growth Factor Receptor 2-Positive Breast Cancer

Metastatic Hormone-Receptor Positive Breast Cancer